Which has higher valuation and earnings, ENGN or KYTX?

Kyverna Therapeutics is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio enGene N/A N/A -$117.30M -$2.17 N/A Kyverna Therapeutics N/A N/A -$161.31M -$3.28 N/A

Is ENGN or KYTX more profitable?

enGene's return on equity of -56.06% beat Kyverna Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets enGene N/A -56.06% -45.64% Kyverna Therapeutics N/A -81.88% -64.87%

Does the media refer more to ENGN or KYTX?

In the previous week, enGene had 4 more articles in the media than Kyverna Therapeutics. MarketBeat recorded 7 mentions for enGene and 3 mentions for Kyverna Therapeutics. Kyverna Therapeutics' average media sentiment score of 0.56 beat enGene's score of -0.30 indicating that Kyverna Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment enGene 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Kyverna Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, BNTC or ENGN?

Benitec Biopharma is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Benitec Biopharma N/A N/A -$37.92M -$1.14 N/A enGene N/A N/A -$117.30M -$2.17 N/A

Is BNTC or ENGN more profitable?

Benitec Biopharma's return on equity of -34.82% beat enGene's return on equity. Company Net Margins Return on Equity Return on Assets Benitec Biopharma N/A -34.82% -34.11% enGene N/A -56.06% -45.64%

Which has stronger valuation & earnings, PRTA or ENGN?

enGene has lower revenue, but higher earnings than Prothena. Prothena is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Prothena $9.68M 49.32 -$244.09M -$0.84 N/A enGene N/A N/A -$117.30M -$2.17 N/A

Is PRTA or ENGN more profitable?

enGene has a net margin of 0.00% compared to Prothena's net margin of -80.68%. Prothena's return on equity of -16.45% beat enGene's return on equity. Company Net Margins Return on Equity Return on Assets Prothena -80.68% -16.45% -14.51% enGene N/A -56.06% -45.64%

Does the media prefer PRTA or ENGN?

In the previous week, Prothena and Prothena both had 7 articles in the media. Prothena's average media sentiment score of 0.35 beat enGene's score of -0.30 indicating that Prothena is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prothena 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral enGene 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Is ENGN or CBIO more profitable?

enGene's return on equity of -56.06% beat Crescent Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets enGene N/A -56.06% -45.64% Crescent Biopharma N/A -101.50% -86.86%

Does the media favor ENGN or CBIO?

In the previous week, Crescent Biopharma had 3 more articles in the media than enGene. MarketBeat recorded 10 mentions for Crescent Biopharma and 7 mentions for enGene. Crescent Biopharma's average media sentiment score of 0.13 beat enGene's score of -0.30 indicating that Crescent Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment enGene 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Crescent Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings & valuation, ENGN or CABA?

Cabaletta Bio is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio enGene N/A N/A -$117.30M -$2.17 N/A Cabaletta Bio N/A N/A -$167.86M -$1.96 N/A

Is ENGN or CABA more profitable?

enGene's return on equity of -56.06% beat Cabaletta Bio's return on equity. Company Net Margins Return on Equity Return on Assets enGene N/A -56.06% -45.64% Cabaletta Bio N/A -131.58% -96.46%

Does the media favor ENGN or CABA?

In the previous week, enGene had 6 more articles in the media than Cabaletta Bio. MarketBeat recorded 7 mentions for enGene and 1 mentions for Cabaletta Bio. Cabaletta Bio's average media sentiment score of 1.67 beat enGene's score of -0.30 indicating that Cabaletta Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment enGene 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Cabaletta Bio 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

enGene (ENGN) Competitors

$1.75 -0.05 (-2.78%)

As of 04:00 PM Eastern

Compare

ENGN vs. KYTX, BNTC, PRTA, CBIO, and CABA

Should you buy enGene stock or one of its competitors? enGene's main competitors and comparable companies include Kyverna Therapeutics (KYTX), Benitec Biopharma (BNTC), Prothena (PRTA), Crescent Biopharma (CBIO), and Cabaletta Bio (CABA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does enGene compare to Kyverna Therapeutics?

enGene (NASDAQ:ENGN) and Kyverna Therapeutics (NASDAQ:KYTX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability, media sentiment and earnings.

enGene has a beta of -0.28, suggesting that its share price is 128% less volatile than the broader market. Comparatively, Kyverna Therapeutics has a beta of 1.93, suggesting that its share price is 93% more volatile than the broader market.

Kyverna Therapeutics is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
enGene	N/A	N/A	-$117.30M	-$2.17	N/A
Kyverna Therapeutics	N/A	N/A	-$161.31M	-$3.28	N/A

enGene's return on equity of -56.06% beat Kyverna Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
enGene	N/A	-56.06%	-45.64%
Kyverna Therapeutics	N/A	-81.88%	-64.87%

64.2% of enGene shares are held by institutional investors. Comparatively, 18.1% of Kyverna Therapeutics shares are held by institutional investors. 10.5% of enGene shares are held by company insiders. Comparatively, 17.6% of Kyverna Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

enGene presently has a consensus target price of $11.05, indicating a potential upside of 531.17%. Kyverna Therapeutics has a consensus target price of $30.00, indicating a potential upside of 280.23%. Given enGene's higher probable upside, analysts clearly believe enGene is more favorable than Kyverna Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
enGene	2 Sell rating(s)	8 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.14
Kyverna Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, enGene had 4 more articles in the media than Kyverna Therapeutics. MarketBeat recorded 7 mentions for enGene and 3 mentions for Kyverna Therapeutics. Kyverna Therapeutics' average media sentiment score of 0.56 beat enGene's score of -0.30 indicating that Kyverna Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
enGene	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Kyverna Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

enGene beats Kyverna Therapeutics on 8 of the 13 factors compared between the two stocks.

How does enGene compare to Benitec Biopharma?

Benitec Biopharma (NASDAQ:BNTC) and enGene (NASDAQ:ENGN) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, profitability, risk, analyst recommendations, dividends and media sentiment.

Benitec Biopharma has a beta of 0.28, suggesting that its share price is 72% less volatile than the broader market. Comparatively, enGene has a beta of -0.28, suggesting that its share price is 128% less volatile than the broader market.

Benitec Biopharma's return on equity of -34.82% beat enGene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Benitec Biopharma	N/A	-34.82%	-34.11%
enGene	N/A	-56.06%	-45.64%

52.2% of Benitec Biopharma shares are owned by institutional investors. Comparatively, 64.2% of enGene shares are owned by institutional investors. 4.8% of Benitec Biopharma shares are owned by company insiders. Comparatively, 10.5% of enGene shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Benitec Biopharma currently has a consensus price target of $24.80, indicating a potential upside of 79.97%. enGene has a consensus price target of $11.05, indicating a potential upside of 531.17%. Given enGene's higher possible upside, analysts plainly believe enGene is more favorable than Benitec Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Benitec Biopharma	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60
enGene	2 Sell rating(s)	8 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.14

In the previous week, enGene had 7 more articles in the media than Benitec Biopharma. MarketBeat recorded 7 mentions for enGene and 0 mentions for Benitec Biopharma. Benitec Biopharma's average media sentiment score of 0.00 beat enGene's score of -0.30 indicating that Benitec Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Benitec Biopharma	Neutral
enGene	Neutral

Benitec Biopharma is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Benitec Biopharma	N/A	N/A	-$37.92M	-$1.14	N/A
enGene	N/A	N/A	-$117.30M	-$2.17	N/A

Summary

Benitec Biopharma beats enGene on 8 of the 13 factors compared between the two stocks.

How does enGene compare to Prothena?

Prothena (NASDAQ:PRTA) and enGene (NASDAQ:ENGN) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership, analyst recommendations and media sentiment.

Prothena has a beta of -0.29, suggesting that its stock price is 129% less volatile than the broader market. Comparatively, enGene has a beta of -0.28, suggesting that its stock price is 128% less volatile than the broader market.

enGene has lower revenue, but higher earnings than Prothena. Prothena is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prothena	$9.68M	49.32	-$244.09M	-$0.84	N/A
enGene	N/A	N/A	-$117.30M	-$2.17	N/A

In the previous week, Prothena and Prothena both had 7 articles in the media. Prothena's average media sentiment score of 0.35 beat enGene's score of -0.30 indicating that Prothena is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prothena	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
enGene	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Prothena currently has a consensus target price of $23.75, suggesting a potential upside of 160.42%. enGene has a consensus target price of $11.05, suggesting a potential upside of 531.17%. Given enGene's higher probable upside, analysts clearly believe enGene is more favorable than Prothena.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prothena	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
enGene	2 Sell rating(s)	8 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.14

97.1% of Prothena shares are owned by institutional investors. Comparatively, 64.2% of enGene shares are owned by institutional investors. 10.4% of Prothena shares are owned by insiders. Comparatively, 10.5% of enGene shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

enGene has a net margin of 0.00% compared to Prothena's net margin of -80.68%. Prothena's return on equity of -16.45% beat enGene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prothena	-80.68%	-16.45%	-14.51%
enGene	N/A	-56.06%	-45.64%

Summary

Prothena beats enGene on 9 of the 15 factors compared between the two stocks.

How does enGene compare to Crescent Biopharma?

enGene (NASDAQ:ENGN) and Crescent Biopharma (NASDAQ:CBIO) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, valuation, media sentiment, profitability and risk.

enGene has higher earnings, but lower revenue than Crescent Biopharma. Crescent Biopharma is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
enGene	N/A	N/A	-$117.30M	-$2.17	N/A
Crescent Biopharma	$10.84M	59.38	-$153.94M	-$6.72	N/A

64.2% of enGene shares are held by institutional investors. Comparatively, 75.2% of Crescent Biopharma shares are held by institutional investors. 10.5% of enGene shares are held by insiders. Comparatively, 24.8% of Crescent Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

enGene has a beta of -0.28, suggesting that its stock price is 128% less volatile than the broader market. Comparatively, Crescent Biopharma has a beta of 1.23, suggesting that its stock price is 23% more volatile than the broader market.

enGene's return on equity of -56.06% beat Crescent Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
enGene	N/A	-56.06%	-45.64%
Crescent Biopharma	N/A	-101.50%	-86.86%

enGene currently has a consensus price target of $11.05, indicating a potential upside of 531.17%. Crescent Biopharma has a consensus price target of $29.40, indicating a potential upside of 69.65%. Given enGene's higher possible upside, equities research analysts plainly believe enGene is more favorable than Crescent Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
enGene	2 Sell rating(s)	8 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.14
Crescent Biopharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

In the previous week, Crescent Biopharma had 3 more articles in the media than enGene. MarketBeat recorded 10 mentions for Crescent Biopharma and 7 mentions for enGene. Crescent Biopharma's average media sentiment score of 0.13 beat enGene's score of -0.30 indicating that Crescent Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
enGene	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Crescent Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Crescent Biopharma beats enGene on 8 of the 15 factors compared between the two stocks.

How does enGene compare to Cabaletta Bio?

enGene (NASDAQ:ENGN) and Cabaletta Bio (NASDAQ:CABA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, media sentiment, risk, valuation, earnings and dividends.

enGene has a beta of -0.28, meaning that its stock price is 128% less volatile than the broader market. Comparatively, Cabaletta Bio has a beta of 3.3, meaning that its stock price is 230% more volatile than the broader market.

64.2% of enGene shares are held by institutional investors. 10.5% of enGene shares are held by insiders. Comparatively, 6.4% of Cabaletta Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

enGene currently has a consensus price target of $11.05, indicating a potential upside of 531.17%. Cabaletta Bio has a consensus price target of $15.50, indicating a potential upside of 453.57%. Given enGene's higher possible upside, research analysts plainly believe enGene is more favorable than Cabaletta Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
enGene	2 Sell rating(s)	8 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.14
Cabaletta Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

enGene's return on equity of -56.06% beat Cabaletta Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
enGene	N/A	-56.06%	-45.64%
Cabaletta Bio	N/A	-131.58%	-96.46%

In the previous week, enGene had 6 more articles in the media than Cabaletta Bio. MarketBeat recorded 7 mentions for enGene and 1 mentions for Cabaletta Bio. Cabaletta Bio's average media sentiment score of 1.67 beat enGene's score of -0.30 indicating that Cabaletta Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
enGene	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Cabaletta Bio	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Cabaletta Bio is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
enGene	N/A	N/A	-$117.30M	-$2.17	N/A
Cabaletta Bio	N/A	N/A	-$167.86M	-$1.96	N/A

Summary

enGene beats Cabaletta Bio on 8 of the 13 factors compared between the two stocks.

Get enGene News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ENGN vs. The Competition

Export

Metric	enGene	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$120.57M	$3.70B	$7.02B	$12.98B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-0.81	5.30	210.34	20.96
Price / Sales	N/A	1,255.26	588.78	86.31
Price / Cash	N/A	44.95	28.89	37.42
Price / Book	0.67	17.66	11.27	6.42
Net Income	-$117.30M	-$13.25M	$3.45B	$347.03M
7 Day Performance	-1.13%	5.36%	3.56%	2.48%
1 Month Performance	-7.89%	-1.74%	-0.58%	-1.04%
1 Year Performance	-52.45%	61.36%	77.52%	23.22%

enGene Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ENGN enGene	2.9532 of 5 stars	$1.75 -2.8%	$11.05 +531.2%	-51.1%	$120.57M	N/A	N/A	31
KYTX Kyverna Therapeutics	2.1224 of 5 stars	$7.92 +2.1%	$30.00 +279.0%	+145.7%	$479.33M	N/A	N/A	96	News Coverage Upcoming Earnings Gap Up
BNTC Benitec Biopharma	1.3745 of 5 stars	$13.39 +2.0%	$24.80 +85.2%	+15.5%	$460.63M	N/A	N/A	20
PRTA Prothena	2.855 of 5 stars	$8.79 +2.5%	$23.75 +170.1%	+13.9%	$460.39M	$57.94M	N/A	130	Earnings Report
CBIO Crescent Biopharma	2.405 of 5 stars	$16.61 +1.1%	$29.40 +77.0%	+31.1%	$457.77M	$10.84M	N/A	50

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ENGN) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

enGene (ENGN) Competitors

ENGN vs. KYTX, BNTC, PRTA, CBIO, and CABA

How does enGene compare to Kyverna Therapeutics?

Summary

How does enGene compare to Benitec Biopharma?

Summary

How does enGene compare to Prothena?

Summary

How does enGene compare to Crescent Biopharma?

Summary

How does enGene compare to Cabaletta Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENGN vs. The Competition

enGene Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

enGene (ENGN) Competitors

ENGN vs. KYTX, BNTC, PRTA, CBIO, and CABA

How does enGene compare to Kyverna Therapeutics?

Which has more risk & volatility, ENGN or KYTX?

Which has higher valuation and earnings, ENGN or KYTX?

Is ENGN or KYTX more profitable?

Do institutionals and insiders have more ownership in ENGN or KYTX?

Do analysts rate ENGN or KYTX?

Does the media refer more to ENGN or KYTX?

Summary

How does enGene compare to Benitec Biopharma?

Which has more volatility & risk, BNTC or ENGN?

Is BNTC or ENGN more profitable?

Do institutionals & insiders have more ownership in BNTC or ENGN?

Do analysts recommend BNTC or ENGN?

Does the media prefer BNTC or ENGN?

Which has higher earnings & valuation, BNTC or ENGN?

Summary

How does enGene compare to Prothena?

Which has more volatility and risk, PRTA or ENGN?

Which has stronger valuation & earnings, PRTA or ENGN?

Does the media prefer PRTA or ENGN?

Do analysts prefer PRTA or ENGN?

Do insiders and institutionals hold more shares of PRTA or ENGN?

Is PRTA or ENGN more profitable?

Summary

How does enGene compare to Crescent Biopharma?

Which has better earnings & valuation, ENGN or CBIO?

Do institutionals and insiders have more ownership in ENGN or CBIO?

Which has more volatility & risk, ENGN or CBIO?

Is ENGN or CBIO more profitable?

Do analysts rate ENGN or CBIO?

Does the media favor ENGN or CBIO?

Summary

How does enGene compare to Cabaletta Bio?

Which has more risk and volatility, ENGN or CABA?

Do insiders & institutionals believe in ENGN or CABA?

Do analysts prefer ENGN or CABA?

Is ENGN or CABA more profitable?

Does the media favor ENGN or CABA?

Which has higher earnings & valuation, ENGN or CABA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENGN vs. The Competition

enGene Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools